Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ, O'Connell RL, Banerjee S, Mileshkin L, Sykes P, Beale P, Fisher A, Bonaventura A, Millan D, Nottley S, Benson C, Hamilton A, Sjoquist K, Alexander L, Kelly C, Carty K, Divers L, Bradshaw N, Friedlander M; PARAGON investigators. Edmondson RJ, et al. Among authors: sjoquist k. Gynecol Oncol. 2021 Dec;163(3):524-530. doi: 10.1016/j.ygyno.2021.09.010. Epub 2021 Oct 5. Gynecol Oncol. 2021. PMID: 34625284 Clinical Trial.
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
Sjoquist KM, Friedlander ML, O'Connell RL, Voysey M, King MT, Stockler MR, Oza AM, Gillies K, Martyn JK, Butow PN. Sjoquist KM, et al. Oncologist. 2013;18(11):1221-8. doi: 10.1634/theoncologist.2013-0175. Epub 2013 Oct 9. Oncologist. 2013. PMID: 24107972 Free PMC article.
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML, Stockler M, O'Connell R, Voysey M, Oza A, Gillies K, Donovan H, Martyn J, Sjoquist K, Butow P, King MT; Symptom Benefit Study Group. Friedlander ML, et al. Among authors: sjoquist k. Int J Gynecol Cancer. 2014 Jun;24(5):857-64. doi: 10.1097/IGC.0000000000000147. Int J Gynecol Cancer. 2014. PMID: 24844219
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT, Stockler MR, Butow P, O'Connell R, Voysey M, Oza AM, Gillies K, Donovan HS, Mercieca-Bebber R, Martyn J, Sjoquist K, Friedlander ML. King MT, et al. Among authors: sjoquist k. Int J Gynecol Cancer. 2014 Jun;24(5):865-73. doi: 10.1097/IGC.0000000000000167. Int J Gynecol Cancer. 2014. PMID: 24844220
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
Ferraro D, Goldstein D, O'Connell RL, Zalcberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, Gebski VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J; behalf of the the Australasian Gastro-Intestinal Trials Group. Ferraro D, et al. Among authors: sjoquist km. Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7. doi: 10.1007/s00280-016-3089-4. Epub 2016 Jun 22. Cancer Chemother Pharmacol. 2016. PMID: 27335026 Clinical Trial.
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Bonaventura A, et al. Int J Gynecol Cancer. 2017 Jun;27(5):900-906. doi: 10.1097/IGC.0000000000000978. Int J Gynecol Cancer. 2017. PMID: 28498256 Clinical Trial.
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
Vasista A, Stockler M, Martin A, Pavlakis N, Sjoquist K, Goldstein D, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Nott L, Snow S, Burge M, Harris D, Jonker D, Chua YJ, Epstein R, Bonaventura A, Kiely B. Vasista A, et al. Among authors: sjoquist k. Oncologist. 2019 Nov;24(11):e1102-e1107. doi: 10.1634/theoncologist.2018-0613. Epub 2019 Apr 1. Oncologist. 2019. PMID: 30936377 Free PMC article. Clinical Trial.
53 results